Abstract: Compounds of formula I wherein: R1 is pyridyl optionally substituted with halogen, C1-4 alkyl, C1-4 alkenyl, CN, Me2N, CO2Me, OMe, aryl, heterocyclyl, or R4; R2 is CF3; halogen; CN; branched or unbranched C1-8 alkyl; branched or unbranched C1-8 alkenyl; C3-8 cycloalkyl optionally substituted with OH, CN, or methoxy; C1-8 alkoxy; C1-4 alkyloxyalkyl; C1-8 alkylthio; C1-4 alkylthioalkyl; C1-8 dialkylamino; C1-4 dialkylaminoalkyl; CO2R4; or aryl connected to the triazole in any position that makes a stable bond and wherein the aryl thereof is optionally substituted with halogen, C1-4 alkyl, C1-4 alkenyl, CN, Me2N, CO2Me, OMe, aryl, heterocyclyl, or R4; L is —NHC(O)—; —NHC(O)O—; —NHC(O)C(O)—; —NHC(S)—; —NH—; —NHC(O)NH—; —NHC(S)NH—; —NHCH2—; —NHCH(R5)—, wherein R5 is H, CN, C1-6 alkyl, C1-6 alkyloxyalkyl, C1-6 alkylthioalkyl, C1-6 alkylsulfinylalkyl, C1-6 alkylsulfonylalkyl, C3-6 cycloalk

Abstract: The present patent application relates to new substituted 3-phenoxy- or 3-phenylalkyloxy-2-phenyl-propylamines of general formula 1, processes for preparing them and their use as pharmaceutical compositions.

Abstract: The present invention relates to new medicament compositions based on anticholinergic compounds, which have a long-lasting effect, and &bgr;-mimetics, which have a long-lasting effect, processes for their production and their use in the therapy of respiratory ailments.

Abstract: New disubstituted bicyclic heterocycles of general formula Ra—A—Het—B—Ar—E  (I) Compounds of general formula I, wherein E is an RbNH—C(═NH)— group, have valuable pharmacological properties, particularly a thrombin-inhibiting effect and the effect of prolonging thrombin time, and those wherein E is a cyano group, are valuable intermediates for preparing the other compounds of general formula I.

Abstract: A process for making compound of formula I from a phenylpropanolamine salt of formula II wherein: R1 is hydrogen or a lower alkyl group; each R2 is independently a hydrogen, halogen, lower alkyl group, lower alkoxy groups, lower alkyl group substituted with 1 to 5 halogens, lower alkoxy groups substituted with 1 to 5 halogens, or both R2 together when on adjacent carbons constitute a —O(CH2)xO— where x is 1 to 4, thereby forming a ring structure fused with the phenyl group; R3 is a C1-C8-alkyl group, a C1-C12-aralkyl group, C1-C12-alkaryl group, or a phenyl group, each optionally substituted by 1 to 5 substituents selected from halogen, hydroxy, or C1-C6-alkyl; and HX is an equivalent of an organic or inorganic acid, the process comprising: (a) acylating the phenylpropanolamine salt of formula II with an acylating agent in a solvent at elevated temperature to make a reaction mixture containing an O-acylated phenylpropanolamine salt of formula III which can

Abstract: Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines of general formula 1: wherein: R1 and R2, which are identical or different, are each hydrogen, C1-C6-alkyl, C1--C6-alkyloxy, OH, F, Cl, or Br; R3 is hydrogen, F, Cl, Br, methyl, ethyl, OH, or methoxy; R4 and R5, which are identical or different, are each hydrogen, methyl, or ethyl; R6 is hydrogen; X is NH2, NH—(C1-C6-alkyl), N(C1-C6-alkyl)2, the two C1-C6-alkyl groups of which are identical or different, NH—COH, NH—CO(C1-C6-alkyl), or F; A is —(CH2)3—, —CH2—CH2—O—, —CH2—O—CH2—, —(CH2)4—, —CH(C1-C6-alkyl)-O—CH2—, —(CH2)2—O—CH2—, —(CH2)3—O—, —(CH2)5—, —CH2—O—(CH2)3—, —(CH2)2—O—(CH2)2—, —(CH2)3—O—CH2—, —(CH2)4—O—, —CH2—O—CH2—CH2—O—,

Abstract: The present invention relates to urethanes derived from azacycloalkanes and the thio and dithio analogues thereof of general formula wherein m, n, A, X, Y, E and R1 to R8 are defined as in claim 1, the enantiomers, diastereomers and the salts thereof, particularly the physiologically acceptable acid addition salts thereof which have valuable properties, particularly an inhibitory effect on cholesterol biosynthesis, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Abstract: The invention relates to new compounds of general formula I and the pharmaceutically acceptable salts thereof, wherein A, B, Z, R1, R2, R3 and m are defined as in the specification, processes for preparing them and pharmaceutical compositions containing these compounds. The compounds are valuable neurokinin (tachykinin) antagonists.

Abstract: Pyranoside derivatives of the formula I wherein 1, m and n independently of one another denote an integer chosen from 0, 1, 2, 3 and 4 and 1+m+n≦4. These are are LTB4-antagonists. Also disclosed are processes for making these compounds.

Abstract: The invention relates to the use of pramipexol as a pharmaceutical composition having an antidepressant activity.

Abstract: The present invention relates to an improved process for preparing L-phenylephrine hydrochloride 3 on an industrial scale by asymmetric hydrogenation as the key step and a special sequence of subsequent steps, using [Rh(COD)Cl]2 as catalyst and a chiral, two-pronged phosphine ligand such as (2R,4R)-4-(dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonyl-pyrrolidine as the catalyst system.

Abstract: The present invention relates to orally administered suspensions of pharmaceutical active substances of the NSAID type, particularly the antirheumatic agent Meloxicam, which are stabilized by the addition of small amounts of highly dispersed silicon dioxide using high shear forces and adding small amounts of hydrophilic polymers to form a three-dimensional siloid structure, and a process for the preparation thereof.

Abstract: This invention discloses hydrophilic additives in polysiloxane gels, elastomers and coatings, and novel processes for producing them. The process comprises:(a) redistributing into polysiloxane-polyether copolymers an unsaturated silane or siloxane,(b) adding to the mixture of reagents a catalytically effective amount of a basic catalyst; and(c) heating the reaction mixture to effect reaction.Novel siloxane structures of unsaturated aliphatic modified polyerther siloxane copolymers are also taught.

Abstract: Dissolved silanes, silicones and silicates from solvents used in the slurry phase Direct Synthesis of alkoxysilanes are removed by adding a carboxylic acid such as formic acid to generate filterable precipitates and reusable solvent. The solvents are thereby remediated and made suitable for reuse in Direct Synthesis processes. Foaming is reduced with the remediated solvent and silicon conversion rates are higher. The precipitates are easily filtered and retain negligible quantities of solvent.

Abstract: Disclosed is a process for making isocyanatoorganosilane by adding a carbamatoorganosilane of the general formula to an inert liquid medium and holding the mixture thus formed at a temperature and pressure effective to convert said carbamatoorganosilane to isocyanatoorganosilane.

Abstract: The present invention discloses blends of silanes and specific silicas, characterized in that when the blend is compounded into a rubber formulation even after 4 months of storage following formation of the blend, an unexpectedly high proportion of the silane present is available as a coupling and reinforcing agent for the rubber formulation. Over 80% and even over 90% of the silica can be extracted or described from the blend even 4 months after formation of the blend, and rubber formulation properties indicate high availability of the silane for coupling and reinforcement.

Abstract: Certain members of the class of N-silylalkyl-aspartic acid esters, when used to endcap polyurethane polymers, offer moisture curable, one-part sealant formulations having significantly improved physical property improvements over other members of the same class of organofunctional silanes. More specifically, polyurethane polymers terminated with either the dibutyl or diethyl maleate/primary aminoalkyl silane addition product offer sealants which substantially outperform comparative sealants obtained using polymers endcapped with other olefinic carboxylate ester (dimethyl maleate, dimethyl crotonate) or nitrile (acrylonitrile)/primary aminoalkyl silane addition products. Additionally, sealant formulations incorporating the dibutyl or diethyl maleate/primary aminoalkyl silane terminated polymers demonstrate unexpected improvements in both elongation and tensile strength performance. The dibutyl maleate and dimethyl maleate based polymers give significant increase in tear resistance.

Abstract: The present invention relates to diesel fuel and lubrication oil defoaming agents, and crude oil demulsifiers, as well as methods for using same. In particular, the defoaming agents and demulsifiers are comprised of copolymers which have structures constituting a backbone of polysiloxane onto which is grafted an organic group. These structures comprise a polymer of the formula MD.sub.x D'.sub.y D".sub.z M, where M is O.sub.0.5 Si(CH.sub.3).sub.3, D is a OSi(CH.sub.3).sub.2, D' is OSi(CH.sub.3)R, D" is OSi(CH.sub.3)R', R is a polyhydric C.sub.6 -C.sub.28 organic group, R' is a phenol derivative or a long chain aliphatic group or polyethers, z is between 0 and 80, x+y+z is between 10-200, x/z is .gtoreq.1, and x/(y+z) is between about 1 and about 5, or formula M'D.sub.a M' where M' is O.sub.0.5 Si(CH.sub.3).sub.2 R, a is between 4-10, and R and D are the same as defined above.

Abstract: It has been discovered that organoamine modified siloxane alkoxylates overcome the antagonism associated with nonionic trisiloxane alkoxylates on pesticide uptake in plants. The organoamine modified siloxane alkoxylates of the present invention have the average general formula: AMe.sub.2 SiO[(Me).sub.2 SiO].sub.x [MeSi(Z)O].sub.y SiMe.sub.2 A, wherein x=0 to 1, y=0 to 2, with the proviso than when y=0, A is Z, A=is Z or Me, Z=RO(R.sup.1).sub.n R.sup.2 N(R.sup.3).sub.2, R is a divalent organic group having from 2 to 4 carbon atoms, R.sup.1 is an alkyleneoxide group containing 2 to 4 carbon atoms, R.sup.2 is a divalent organic group containing 2 to 6 carbons, R.sup.3 may be hydrogen, an alkyl radical with 1 to 4 carbons, an amino alkyl of one to four carbons, or an alkyl of 2 to 4 carbon atoms which may have hydroxy substitutions thereon. Each R.sup.3 may be the same or different.When R.sup.1 is oxyethylene, n is from 1 to 10, preferably 2 to 5. When R.sup.

Abstract: Disclosed are aqueous polyurethane dispersions prepared from polyester polyols having 0.95 to 1.5 equivalents of carboxylic functionality thereon per equivalent of polyol, the dispersions also containing a nonionic surfactant component wherein the ratio by weight of said carboxylic functionality to said nonionic surfactant component is 1:2.5 to 1:0.5. The dispersions are particularly adapted to the formation of thin wall articles exhibiting greatly improved properties.